Precision experts Travis Harrison: VP, Bioassay Solutions (Precision for Medicine), Reed Lyon: Director, Business Development (Precision for Medicine), and Pallavi Chhabra: Director, Business Development (Precision for Medicine) will be exhibiting at ASGCT Annual from May 16-19 in Washington, D.C. Travis Harrison will also be giving a presentation on, “Key Considerations for Design and Implementation of Nab Bioassays in Gene Therapy Development” on May 17 at 1PM EST.
The commercialization of cell and gene therapies raises several complex conversations and questions for employers and payers. Without proper solutions and partnerships, employers and health insurers will be held responsible for extreme medical costs associated with gene therapy.
In recent years, the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are transforming the way diseases are treated but are also aiming to cure entirely new patient populations. 2021 saw record-breaking investments across the board, with a 16% increase from the previous year, totaling $23.1billion raised. However, the question remains as to whether this will continue in 2022. As public markets adjust and the economy recovers in early 2022, investments in the cell and gene therapy space may plateau.
Precision will be at this year’s Meeting on the Med conference from April 20 – 22nd in Barcelona, Spain. Connect with our team of experts as they lead meaningful discussions throughout this event, providing insights into the clinical development, manufacturing, and commercialization of cell and gene therapies.
Did you miss our presentation at this year’s World EPA Congress in Amsterdam? Precision experts Richard Macaulay (VP, Global Pricing and Market Access) and David Carr (Director, Global Pricing and Market Access) presented “Gene Therapies Market Access: Lessons From The Past, Future Best Practice” which analyzes the access success of launched gene therapies and draws best-practice learnings for future gene therapies.
In January, the Alliance for Regenerative Medicine (ARM) released its State of the Industry Briefing which highlighted a record-breaking year for 2021. $23.1B raised for the advanced medicines sector (a 16% increase from 2020), 2,261 ongoing regenerative medicine clinical trials globally, and the evolution from treating and curing rare monogenetic diseases to more prevalent indications. Could we see 10-20 approvals each year by 2025?
PRECISIONxtract Launches OncoGenius, Empowering Oncology Brands With New Insights From Provider-level Data
Recent acquisition of veteran pharmaceutical market consultancy Oncology Reimbursement Management propels and further elevates Precision’s oncology commercialization solutions.
Precision will be at this year’s Gene Therapy for Rare Disorders from March 7 – 10th in Boston. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization of therapies for rare genetic disorders.
White Paper: Considerations for the Clinical Development of Cell & Gene Therapies (Part 2: Gene Therapies)
Advances in stem cell technology, combined with the increasing prevalence of chronic diseases, are driving rapid growth in the regenerative medicine category, which is predicted to generate $39.33 billion in revenue by 2023.
White Paper: Considerations for the Clinical Development of Cell & Gene Therapies (Part 1: Cell Therapies)
The regenerative medicine category is predicted to generate $39.33 billion in revenue by 2023, with the fastest growth expected in cell therapy.